Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
Price Band fixed at ₹ 215 to ₹ 226 per Equity Share of face value of ₹ 5 each Bid ...
The company's maiden public issue will open for subscription on Tuesday, August 6, and will close on Thursday, August 8 ...
This promotion waives the ₹1,000 installation charge for new users The offer runs from 26th July to 15th August 2024 ...
Exciting opportunity for customers to upgrade to a Volkswagen: With the introduction of Autofest Mega Exchange Carnival, the Brand is ...
The new entity will seek automatic listing on stock exchanges and according to the scheme of arrangement, each Raymond Ltd ...
The 21-month program will guide aspiring entrepreneurs through a comprehensive journey divided into distinct phases of ideation, innovation, and prototype ...
Galaxy S23 comes with Galaxy AI, Samsung’s suite of built-in and cloud-based AI features Samsung is Democratising Galaxy AI Experience with ...
NE NEWS SERVICE GANDHINAGAR, APRIL 9 The Gujarat government has notified a public holiday on May 7 on account of ...
NE BUSINESS BUREAU MUMBAI, MARCH 19 Sun Pharmaceutical Industries Limited on Tuesday announced that the Australian Therapeutic Goods Administration (TGA) ...
Email:
ne.gowri1964@gmail.com
Phone:
9643255068
© 2021 all right reserved by Navjeevanexpress.com. Consulted by MediaHives.com